Compare BOX & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | IDYA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | 2912 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.5B |
| IPO Year | 2014 | 2019 |
| Metric | BOX | IDYA |
|---|---|---|
| Price | $30.54 | $36.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $35.57 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $506,142,000.00 | $218,710,000.00 |
| Revenue This Year | $9.41 | N/A |
| Revenue Next Year | $8.15 | $201.05 |
| P/E Ratio | $393.13 | ★ N/A |
| Revenue Growth | 26.98 | ★ 3024.43 |
| 52 Week Low | $21.34 | $21.33 |
| 52 Week High | $33.88 | $40.58 |
| Indicator | BOX | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 69.68 | 55.03 |
| Support Level | $29.13 | $29.51 |
| Resistance Level | $30.69 | $38.17 |
| Average True Range (ATR) | 1.01 | 1.56 |
| MACD | 0.33 | -0.40 |
| Stochastic Oscillator | 77.92 | 23.52 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.